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MicroRNA interactome analysis 
predicts post-transcriptional 
regulation of ADRB2 and PPP3R1 
in the hypercholesterolemic 
myocardium
Bence Ágg  1,2,3, Tamás Baranyai1, András Makkos1, Borbála Vető4, Nóra Faragó5, 
Ágnes Zvara5, Zoltán Giricz  1, Dániel V. Veres6, Péter Csermely  6, Tamás Arányi4, 
László G. Puskás5, Zoltán V. Varga1 & Péter Ferdinandy  1,2,7
Little is known about the molecular mechanism including microRNAs (miRNA) in hypercholesterolemia-
induced cardiac dysfunction. We aimed to explore novel hypercholesterolemia-induced pathway 
alterations in the heart by an unbiased approach based on miRNA omics, target prediction and 
validation. With miRNA microarray we identified forty-seven upregulated and ten downregulated 
miRNAs in hypercholesterolemic rat hearts compared to the normocholesterolemic group. Eleven 
mRNAs with at least 4 interacting upregulated miRNAs were selected by a network theoretical 
approach, out of which 3 mRNAs (beta-2 adrenergic receptor [Adrb2], calcineurin B type 1 [Ppp3r1] and 
calcium/calmodulin-dependent serine protein kinase [Cask]) were validated with qRT-PCR and Western 
blot. In hypercholesterolemic hearts, the expression of Adrb2 mRNA was significantly decreased. 
ADRB2 and PPP3R1 protein were significantly downregulated in hypercholesterolemic hearts. The 
direct interaction of Adrb2 with upregulated miRNAs was demonstrated by luciferase reporter assay. 
Gene ontology analysis revealed that the majority of the predicted mRNA changes may contribute 
to the hypercholesterolemia-induced cardiac dysfunction. In summary, the present unbiased target 
prediction approach based on global cardiac miRNA expression profiling revealed for the first time in 
the literature that both the mRNA and protein product of Adrb2 and PPP3R1 protein are decreased in 
the hypercholesterolemic heart.
Although, many guidelines effectively support the treatment of cardiovascular disorders, cardiovascular diseases 
are still the leading cause of mortality and morbidity in developed countries1. The high morbidity and mortality 
of cardiovascular diseases are primarily attributed to the growing prevalence of chronic metabolic diseases, such 
as diabetes mellitus, hypercholesterolemia, obesity, which are well-established risk factors of numerous cardio-
vascular diseases (e.g., chronic heart failure, acute myocardial infarction, etc.)1. Hypercholesterolemia is mainly 
responsible for the development of atherosclerosis, therefore, hypercholesterolemic patients are exposed to more 
severe progression of acute and chronic ischemic heart diseases2. Importantly, it has been also demonstrated 
in preclinical and clinical studies that hypercholesterolemia directly, and independently from the development 
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of atherosclerosis, impairs both systolic and diastolic cardiac function3,4, and exacerbates ischemia/reperfusion 
injury5 possibly via interfering with endogenous protective pathways6–8. However, the underlying mechanism of 
impaired myocardial function due to hypercholesterolemia is still unclear.
It is known that chronic metabolic derangements (e.g., type 2 diabetes mellitus) modify the microRNA 
(miRNA) expression pattern of fundamental metabolic and survival mechanisms of the heart9. MiRNAs are con-
served, non-coding, about 22 nucleotide long RNA molecules, playing pivotal role in the posttranscriptional 
regulation of gene expression both in physiological and pathophysiological conditions10, including diseases of 
the cardiovascular system11–13. Generally, high-throughput miRNA analysis is applied as a screening method 
to identify single targets to investigate in depth. Similarly, we have previously shown that hypercholesterolemia 
alters miRNA expression profile significantly, and as a consequence, decreased expression of miR-25 induces 
oxidative/nitrative stress in the myocardium14. A single miRNA is able to regulate even hundreds of mRNAs, and 
a single mRNA might be targeted by several miRNAs, implying that a slightly changed miRNA expression profile 
might substantially alter multiple pathways simultaneously thereby markedly influencing the phenotype of var-
ious diseases15,16. Therefore, the systematic interpretation of high-throughput methods might be a powerful tool 
to understand the underlying complex mechanisms of cardiovascular disorders17.
Here we aimed to analyze the miRNA expression profile of hypercholesterolemic rat hearts with compre-
hensive bioinformatic methods as recommended in the Position Paper of the European Society of Cardiology 
Working Group on Cellular Biology of the Heart18,19. We developed an unbiased target prediction approach and 
subsequently validated changes in the expression of predicted genes, Adrb2 and Ppp3r1, in case of Adrb2 direct 
interaction with miR-195 and miR-322 was also demonstrated.
The adrenoceptor beta 2 (Adrb2) gene encodes the mRNA and the protein of an adenylate cyclase-activating, 
G-protein coupled adrenergic receptor denoted by the symbols Adrb2 and ADRB2 respectively. While the tran-
scribed mRNA of the protein phosphatase 3, regulatory subunit B, alpha (Ppp3r1) gene is denoted by the same 
symbol (Ppp3r1), its protein product is the calcineurin B type 1 (CNB1) which is one of the two isoforms of the 
regulatory subunit of the calcineurin serine/threonine phosphatase heterodimer enzyme. The mRNA (Cask) and 
protein product (CASK) of calcium/calmodulin dependent serine protein kinase (Cask) gene was also investi-
gated in our study, which could be involved in intracellular calcium mediated signaling pathways20. Furthermore, 
gene ontology analysis revealed that an altered miRNA fingerprint is associated with impaired cardiac function 
and an overactivated protein kinase pattern.
Results
miRNA microarray analysis. Datasets of miRNA microarray analysis of normo- and hypercholesterolemic 
rats from our previous study14 were further analyzed in the present study. The miRNA microarray data were 
deposited in the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) in Minimum Information About a 
Microarray Experiment (MIAME) compliant format with an accession number of E-MTAB-3979. Three hundred 
fifty miRNAs were assayed, among which 120 miRNAs were detectable. Fourty seven miRNAs were upregulated, 
while 10 miRNAs were downregulated in hypercholesterolemic rat hearts as compared to the normocholester-
olemic control rat hearts (Fig. 1A). The expression of 8 altered miRNAs was validated with qRT-PCR (Fig. 1B).
miRNA target prediction and validation. Out of the differentially expressed (47 upregulated and 10 
downregulated) miRNAs 43 upregulated and 8 downregulated miRNAs were further investigated. Four upregu-
lated and two downregulated miRNAs did not meet our inclusion criteria, i.e. these miRNAs were not involved in 
any miRNA-target interactions presented in at least two predicted (miRDB, microRNA.org) or one experimen-
tally validated (miRTarBase) miRNA-target interaction databases. According to previous studies, the regulation 
of target mRNAs by several miRNAs may be synergistic exerting a major effect on the bioavailability of the tar-
get mRNAs21. To find such miRNA target hubs, we constructed a classical miRNA-target network in which the 
nodes represent miRNAs and putative target mRNAs, while edges symbolize miRNA-target interactions (Fig. 2A; 
High-resolution network is available as Supplementary Fig. 1). The total number of putative mRNAs regulated by 
down- and upregulated miRNAs were 79 and 330, respectively, from which 32 mRNAs were theoretically mod-
ulated by both down- and upregulated miRNAs (Fig. 2D). From the indicated 409 mRNAs, 11 mRNA (Adrb2, 
Cask, Lppr4, Mob4, Myt1l, Ppp3r1, Pth, Ptprz1, Sgk1, Stx1a and Wee1) had at least 4 miRNA-target interactions. 
Out of the above 11 mRNAs four miRNA targets, i.e, Adrb2, Sgk1, Ppp3r1 and Cask mRNAs have been selected 
for further validation based on systematical review of the literature (Fig. 2B,C). The results of the PubMed queries 
are shown in Supplementary Table 1, also indicating the number of articles found to be relevant by manual cura-
tion of the search results. As parathyroid hormone (Pth) has negligible expression in the heart according to the 
Human Protein Atlas22, literature mining was not performed for Pth.
The expression of Adrb2 mRNA was significantly downregulated in hypercholesterolemia compared to the 
normocholesterolemic group, however, mRNA expression of Ppp3r1 and Cask was not affected (Fig. 3A). Since 
miRNAs are not necessarily mediating the degradation of mRNAs, but also may repress their translation23, we 
assessed the expression of proteins translated from Adrb2, Ppp3r1 and Cask mRNA, i.e., adrenoceptor beta 2 
(ADRB2), calcineurin B type 1 (CNB1) and calcium/calmodulin dependent serine protein kinase (CASK) 
respectively. Although cardiac ADRB2 and CNB1 were significantly downregulated by hypercholesterolemia, the 
expression of CASK was not altered by hypercholesterolemia (Fig. 3B). Full Western blot images are shown in 
Supplementary Fig. 2.
Out of the selected four targets we did not detect the mRNA expression of Sgk1 in our samples.
The effect of chosen targeting miRNAs (miR-195, miR-322) on ADRB2 protein expression was proven in 
miRNA-luciferase reporter assay, constructed to show miRNA effect on predicted mRNA target. MiR-195 and 
miR-322 inhibited luciferase signal intensity significantly compared to signal detected after transfection with 
non-targeting control miRNA (Fig. 4).
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Gene ontology analysis of predicted mRNAs. To explore biological processes modified by hyper-
cholesterolemia, gene ontology analysis of predicted mRNAs was performed. It clearly showed that downreg-
ulated miRNA-targeted mRNAs were significantly associated with various protein kinase activities, such as 
mitogen-activated protein kinases (Fig. 5A). This implies that the overall protein kinase activity may be increased 
in the hypercholesterolemic myocardium. Among the annotations of upregulated miRNA-targeted mRNAs, 
cardiac function and -development-related processes were significantly enriched and overrepresented (Fig. 5B). 
Similarly, developmental processes were significantly enriched among the common targets of up- and downregu-
lated miRNAs (Supplementary Table 2). Since miRNAs hinder translation of the targeted mRNAs, gene ontology 
analysis indicates that cardiac function and development might be substantially impaired in the myocardium due 
to hypercholesterolemia.
Discussion
In this study, we applied a bioinformatic target prediction followed by experimental target validation to iden-
tify miRNAs and related target genes differentially expressed in the heart of hypercholesterolemic rats. By com-
paring the miRNA expression patterns in myocardial samples from control and hypercholesterolemic rats we 
identified 47 and 10 candidate miRNAs to be upregulated and downregulated, respectively. The comprehensive 
and unbiased bioinformatic analysis of the miRNA-mRNA interactome revealed that both the mRNA and the 
protein product of Adrb2 gene, as well as PPP3R1 protein are decreased in hypercholesterolemia. These novel 
predictions were confirmed by qRT-PCR and Western blot. In case of Adrb2 gene, which showed robust expres-
sion changes on both the protein and the mRNA level, the direct interaction with miR-195 and miR-322 was 
verified. The present miRNA target prediction approach that contributes to the exploration of the background of 
hypercholesterolemia-induced cardiac dysfunction, might be a suitable tool for the global analysis and prediction 
of complex miRNA-mRNA interactions and may reveal relevant targets in other pathologies as well.
We have shown that hypercholesterolemia without atherosclerosis induces diastolic dysfunction14,24,25, 
which has also been verified by others26. Although, mechanistic details in regards of the background of 
hypercholesterolemia-related contractile dysfunction, such as the role of increased oxidative/nitrative stress, 
has been revealed14,27, we still do not understand the complexity of the mechanisms underlying this clinically 
important pathology. It has been proposed that non-coding RNAs, including miRNAs, are among the most 
important regulators and orchestrators of gene expression28. To date, most studies tended to link a particular 
Figure 1. The expression difference in cardiac miRNA due to hypercholesterolemia based on miRNA 
microarray (A). The expression of selected miRNAs has been validated with qRT-PCR (B). ***p < 0.001 vs. 
Control (ΔΔCt method). n = 3–6/group. Downregulated and upregulated miRNAs are indicated in green and 
red, respectively.
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miRNA-mediated biological effect to a single or few selected target genes. However, recent large-scale studies by 
using various transcriptomic and proteomic approaches, clearly demonstrated that even single individual miR-
NAs may alter the expression of hundreds to thousands of genes. Similarly, the mRNA transcriptome regulates 
the expression of miRNAs29, thus, organizing multiple regulatory loops. Moreover, miRNAs are also encoded in 
introns of mRNAs30 complicating the regulatory network even further. Therefore, the interactome of miRNAs and 
mRNAs consists of countless bidirectional connections, and change in the expression of a single RNA may pro-
foundly influence the network dynamics. Thus, in case of significant changes in the expression of multiple miR-
NAs to study the overall effect on gene expression alterations, unbiased computational approaches are required. 
Here we hypothesized that multiple miRNAs regulating the same target would have a profound effect more likely 
than a single miRNA31. Although several computational methods have been developed and tested to date, few 
studies performed complex integration of target prediction of multiple miRNAs followed by experimental valida-
tion and pathway analysis. The most widely used approach is to predict targets for single miRNAs of interest and 
then presume biological function by performing pathway enrichment analysis on the predicted targets. Although 
this approach is straightforward, the predicted biological functions may not be biologically relevant if the pre-
dicted targets are not expressed by the tissues/cells under investigation.
To confirm the overall validity of our target prediction network, gene ontology analysis was performed 
and revealed that supposedly repressed mRNAs are significantly linked to cardiac contraction and develop-
ment, which is in line with previous findings showing that hypercholesterolemia induces cardiac dysfunction14. 
Furthermore, predicted mRNA targets of downregulated miRNAs are significantly associated with the overac-
tivation or promotion of mitogen-activated protein kinases, and it is known that various protein kinases (e.g., 
p38) are overactivated in hypercholesterolemia therefore inhibiting the cardiac response to various stimuli5,32,33.
Based on unbiased target prediction analysis, here we verified that β2-adrenoreceptor is downregulated both 
on the mRNA and the protein level due to hypercholesterolemia, which is associated with impaired diastolic 
function14. Previously, it has been shown that the 3′ UTR region of Adrb2 mRNA is essential to its translation34. 
Indeed, we have successfully demonstrated the direct interaction between Adrb2 mRNA and two upregulated 
miRNAs, namely miR-195 and miR-322, that could explain the changes in the Adrb2 expression. However, we 
could not rule out that other synergistic regulatory pathways (e.g., RNA-binding proteins35, transcription factors 
or epigenetic alterations36) are also influenced by hypercholesterolemia also contributing to the downregulation 
of Adrb2. Although the most abundant β-receptor in the heart is the β1-receptor, β2-receptor-related effects are 
also significant37. MiR-16 Adrb2 mRNA interaction was represented in our analysis as not validated, however 
this interaction was validated experimentally recently38. It has been shown that intravenous infusion of a selective 
β2 adrenergic receptor agonist, salbutamol, enhances cardiac contractility39, therefore, cardiac downregulation 
Figure 2. Interaction network and miRNA target prediction analysis of down- and upregulated miRNAs (A) 
showing the central role of Adrb2, Cask (B) and Ppp3r1 (C) mRNAs. High-resolution network is available as an 
online Supplementary material (Supplementary Fig. 1). Downregulated, upregulated miRNAs and mRNAs are 
indicated in green, red and blue, respectively. Dark blue represents mRNAs with at least 4 target interactions. 
Venn diagram presenting the number of predicted up- and downregulated miRNA targets (D).
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Figure 3. Validation of several predicted miRNA targets. Based on qRT-PCR, Adrb2 mRNA, but not Ppp3r1 
and Cask mRNAs, was significantly downregulated by hypercholesterolemia in the heart compared to the 
control group (A). *p < 0.05 vs. Control (Student’s t-test). n = 6/group. Calcineurin B type 1 (CNB1) translated 
from Ppp3r1 mRNA was significantly downregulated in the hypercholesterolemic myocardium compared 
to the control group (B). *p < 0.05 vs. Control (Student’s t-test). n = 8–9/group. Western blot images are only 
representative.
Figure 4. Luciferase assay validation for selected miRNAs and Adrb2 mRNA 3′UTR interaction. Luciferase 
signal intensity was significantly downregulated by selected targeting miRNAs, also miR-106 and miR-322, 
compared to non-targeting control miRNA (A). *<0.05 vs. non-targeting control, n = 3 (one-way ANOVA 
followed by Dunnett’s post hoc test) Representative maps of Lightswitch luciferase reporter vector (B) and beta-
galactosidase reporter vector (C) used for miRNA luciferase assay.
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of β2-adrenoreceptor could be involved in the mechanism of myocardial dysfunction induced by hypercholes-
terolemia. To date, it is not known whether hypercholesterolemia represses Adrb2 mRNA expression, or if the 
β2 adrenoreceptor signaling abnormalities play a role in the development of hypercholesterolemia. Nevertheless, 
clinical studies report the β2 adrenoreceptor polymorphism as a risk factor for the development of dyslipidemia40. 
Also high LDL level is able to decrease the β2 adrenoreceptor density in porcine arteria media explants41, while 
cholesterol-depletion promotes β2-adrenerg signaling in mouse atria42.
Here we predicted in silico that Ppp3r1 mRNA is significantly suppressed by 6 upregulated miRNAs (predomi-
nantly by the miR-30 family) in hypercholesterolemia. Indeed, although the expression of Ppp3r1 mRNA was not 
decreased by hypercholesterolemia, the CNB1 protein (translational product of Ppp3r1 mRNA) was significantly 
downregulated. This is in accordance with previous findings in glomerular podocytes demonstrating that the 
expression of CNB1 protein is significantly decreased by miR-30 family members without affecting the mRNA 
level. Furthermore, the direct interaction between miR-30 family members with CNB1 mRNA was demonstrated 
by luciferase assays43. It is important to note here that although we utilized the miRNA-target interactions from 
miRTarBase in our software, the experimental evidence for the miRNA-target interaction between miR-30 family 
members and Ppp3r1 was not available in the version of miRTarBase used for the in silico target analysis. This 
literature data suggests that our predictions are in line with an independent experimental verification of the direct 
interaction between Ppp3r1 mRNA and the members of miR-30 family. As our microarray results indicate the 
upregulation of miR-30 family members in hypercholesterolemia, we consider the above experimental data from 
the literature sufficient to explain the observed changes in the expression of CNB1 protein. Therefore, no further 
luciferase reporter assays were performed in case of Ppp3r1 mRNA. It is known that the inhibition of calcineu-
rin pathway (e.g. after renal transplantation) is associated with hypercholesterolemia44. However, it is not clear 
in our study whether the decrease in CNB1 promotes the development of hypercholesterolemia or vice versa. 
The calcineurin signaling pathway plays either an adaptive or a maladaptive role in the development of cardiac 
hypertrophy and heart failure45. It has been shown that overactivated calcineurin pathway deteriorates myocar-
dial adaptive mechanisms, while moderately activated calcineurin, promotes cell survival, for example, following 
ischemia/reperfusion injury or during cardiac hypertrophy45. Accordingly, since calcineurin B regulates the acti-
vation of calcineurin A46, its downregulation due to hypercholesterolemia might contribute to cardiac diastolic 
dysfunction. The above literature data suggest that the expression changes of Ppp3r1 shown in our study might be 
involved in the development of myocardial dysfunction in hypercholesterolemia.
Figure 5. Gene ontology analysis (biological processes) of downregulated miRNA targets highlights 
the uncontrolled activation of mitogen-activated kinase pathways (A), whereas gene ontology analysis 
(biological processes) of upregulated miRNA targets indicates the deterioration of myocardial contractility in 
hypercholesterolemia (B). *p < 0.05, **p < 0.01, ***p < 0.001 vs. Control (Gene ontology enrichment analysis 
with Bonferroni correction).
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In case of our third predicted target, i.e. the mRNA of the Cask gene, we could not find significant change 
either in its gene or protein expression due to hypercholesterolemia. The Cask gene encodes a calcium/
calmodulin-dependent serine protein kinase that has been described to play a role in neurons in regulat-
ing purinergic nociceptive signaling47 and neuronal growth48. Although, we found here that the rodent heart 
expresses Cask, Cask linked miRNAs (i.e. miR-195 and miR-322) do not seem to influence Cask expression itself. 
Differential expression of Cask-linked miRNAs and unaltered expression of Cask could be explained by differ-
ences in the presence of RNA binding protein sites in the predicted target RNA. RNA binding proteins, such as 
members of the Pumilio family, or the HuR protein family are able to bind mRNAs and affect miRNA-mediated 
translational repression. Pumilio members stimulate miRNA-mediated repression, while HuR proteins are capa-
ble of both supressing or facilitating (if HuR binding occurs in AU rich region) miRNA-mediated target sup-
pression49. In accordance, we found consensus sequences for Pumilio binding in Ppp3r1 mRNA, explaining its 
downregulation. Similarly, there are AU-rich HuR binding sequences in the Adrb2 mRNA that may also explain 
Adrb2 downregulation35. However, the Cask mRNA contains HuR binding sequences that very likely inhibit 
miRNA-mediated silencing (by miR-195 and miR-322).
Although according to the Human Protein Atlas Sgk1 is expressed in the heart22, we did not detect the expres-
sion of Sgk1 on the mRNA level in our rat heart samples, suggesting species differences in the expression of this 
gene.
There are some limitations of our present study. Although the target prediction software we used can ana-
lyze the miRNA expression changes qualitatively (i.e. distinction between up- and downregulated miRNAs), it 
cannot handle those paradoxical effects that arise from the complex dynamical aspects of the miRNA mediated 
post-transcriptional regulation, explained in detail by the competing endogenous RNA (ceRNA) hypothesis50. 
This hypothesis can also explain our observation regarding to the internal control groups used for the fine tuning 
of the luciferase reporter assays (Supplementary Fig. 3). Although here we have shown experimental evidences 
for direct miRNA-target interactions that could explain the expression changes of Adrb2 and Ppp3r1 genes on 
the mRNA and protein levels, however, we can not rule out the possibility that there are miRNA-idependent reg-
ulatory pathways that could also contribute to the observed alterations in the expression of these two genes, such 
as changes in the activity of transcription factors, epigenetic changes and other post-transcriptional regulatory 
pathways18. If the novel targets (Adrb2 and Ppp3r1) revealed in the present study may play a role in the cardiac 
phenotype of this hypercholesterolemic animal model needs further investigation.
In conclusion, here we developed a comprehensive, unbiased bioinformatic method to analyze myocardial 
miRNA expression profile in hypercholesterolemic rats and to predict multilevel interactions of miRNAs and 
mRNAs and subsequently validated changes in the predicted genes, Adrb2 and Ppp3r1. We believe, that by using 
similar complex bioinformatic approaches, new and important molecular targets can be revealed in other clini-
cally important pathological conditions.
Methods
Experiments were performed according to the guidelines from Directive 2010/63/EU of the European Parliament 
on the protection of animals used for scientific purposes, and were approved by the local Animal Ethics 
Committee of the University of Szeged.
Experimental protocol. The protocol obtaining miRNA microarray data and myocardial tissue samples of 
normocholesterolemic and hypercholesterolemic rats was described in detail in our previous study14. In the cited 
study, we demonstrated that hypercholesterolemia developed after feeding rats with cholesterol-enriched diet, 
and hypercholesterolemia leads to myocardial dysfunction. Briefly, Wistar rats were fed for 12 weeks with stand-
ard rat chow supplemented or not with 2% cholesterol and 0.25% cholate. After pentobarbital anaesthesia (60 mg/
kg i.p.) and heparinization (500 U/kg i.v.), rat hearts were isolated, perfused retrogradely with Krebs-Henseleit 
buffer and snap frozen in liquid nitrogen. The miRNAs were isolated from ventricular myocardium (n = 6/group) 
according to the manufacturer’s instructions (Roche, Germany) with modifications, as described51. Random pairs 
of the RNA extracted from 6 different samples in each group were pooled, and the obtained 3 samples/group were 
assayed on miRNA microarrays. The expression of certain miRNAs has been validated with quantitative real-time 
polymerase chain reaction (qRT-PCR) as described previously, by using predesigned Taqman microRNA assays 
(Life Technologies, CA, US)14.
Bioinformatic prediction of miRNA targets. A software (miRNAtarget.com, Pharmahungary, Szeged, 
Hungary) was utilized to collect those target genes that had a high probability to be regulated by differentially 
expressed miRNAs identified in this study. With the use of this software we queried miRNA target interactions 
recorded in the Rattus norvegicus specific subset of three publicly available databases, including two predicted 
(miRDB, microRNA.org) and one manually curated, experimentally validated (miRTarBase) sources52–54. 
Another highly accessed predicted database (TargetScan) was also considered as a fourth source of miRNA-target 
interactions, however, it did not contain data specific to rats, and thus it was excluded from the analysis16. 
Databases were downloaded as separate files between 12 and 15 January 2015 (miRDB version 5.0, released in 
August, 2014; microRNA.org release of August, 2010 and miRTarBase release 4.5). In the case of microRNA.org 
only the two bundles with good mirSVR score (a support vector regression based downregulation score rank-
ing miRNA target sites) for both conserved and non-conserved miRNAs were used for this study. The queried 
miRNA-target interaction databases are not tissue specific, the predicted databases (miRDB, microRNA.org) are 
based on the analysis of miRNA and mRNA sequences52–54.
To measure the quality of predicted miRNA-target interactions, target score for miRDB and mirSVR score 
for microRNA.org records were checked by the software. MiRNA-target interactions with scores ≤80.0 and 
≥−1.2 respectively were removed from the result set. To further reduce the ratio of false positive miRNA-target 
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interactions, we excluded all miRNA-target interactions that were only present in one predicted database. 
For this purpose, we defined a compound miRNA-target interaction score giving 0.5 points for each pre-
dicted miRNA-target interaction records and 1 point for an experimentally validated record from miRTar-
Base. MiRNA-target interactions were kept in the resulting dataset for further analysis only if their score was 
greater than or equal to 1. The final output of the software was a miRNA-target network constructed from the 
miRNA-target interactions. The resulting network was visualized with the use of EntOptLayout plugin for 
Cytoscape by applying successive node position and width optimizations steps and achieving a relative entropy 
of 0.01555.
Experimental validation of predicted miRNA targets. After target prediction, selected miRNA targets 
were experimentally validated by PCR, Western blotting and luciferase assay according to the recommendations 
of the European Society of Cardiology Working Group on Cellular Biology of the Heart18.
Selection of miRNA targets for experimental validation. Predicted targets were further selected for exper-
imental validation based on literature review of cellular pathways, possibly involved in hypercholesterolemia-induced 
myocardial dysfunction, i.e. alteration of calcium homeostasis, dysregulation of energy metabolism and oxidative stress. 
PubMed search keywords utilized for the literature mining are shown in Supplementary Table 1.
Total RNA isolation and mRNA qRT-PCR. Total RNA was isolated from ventricular myocardium 
(n = 6/group) with a precipitation method. Briefly, RNAzol® RT (Sigma, MO, US) was added to each sample and 
homogenized with TissueLyser (Qiagen, Germany). Homogenates were centrifuged, and DNA and protein were 
precipitated with nuclease-free water. Furthermore, 4-bromoanisole (Sigma, MO, US), phase separation step was 
incorporated to maximize the DNA elimination. Total RNA was precipitated with isopropanol (vWR, PA, US), 
and pellets were washed twice with ethanol (vWR, PA, US). Finally, total RNA was resuspended in nuclease-free 
water.
Afterwards, cDNA was synthesized from total RNA (measured with NanoDrop [Thermo Fischer Scientific, 
MA, US]) applying Sensifast cDNA synthesis kit (Bioline, UK) according to the manufacturer’s protocol. qRT-PCR 
reactions were performed with a LightCycler® 480 II (Roche, Germany) in the presence of LightCycler® RNA 
Master SYBR Green I (Roche, Germany) and with or without dimethyl sulfoxide (DMSO; 4%; Sigma, MO, US). 
Primers (Integrated DNA Technologies, IA, US) were designed for surface domain of adrenoceptor beta 2 (Adrb2; 
forward: 5′-AACTGGTTGGGCTATGTCAA-3′; reverse: 5′-GTTAGTGTCCTGTCAGGGAG-3′), for calcineurin 
B type 1 (Ppp3r1; forward: 5′-CATCTCCAACCGAGACTCC-3′; reverse: 5′-GGAAAGCGAACCTCAACTTC-3′) 
and for calcium/calmodulin-dependent serine protein kinase (Cask; forward: 5′-TTTCAGAACCCTCCACGCT-3′; 
reverse: 5′-ATCTGTCTCATGTAGTGACTGG-3′). Hypoxanthine-guanine phosphoribosyltransferase (HPRT; 
forward: 5′-GTCCTGTTGATGTGGCCAGT-3′; reverse: 5′-TGCAAATCAAAAGGGACGCA-3′) was used as 
a housekeeping gene. Polymerase was activated for 15 min at 95 °C, and targets were amplified and quantified 
(denaturation: 30 sec at 93 °C; annealing: 30 sec at 52–53 °C; synthesis: 1 min at 72 °C).
Western blot. Snap frozen heart samples (8 and 9 from normo- and hypercholesterolemic groups, respec-
tively) were homogenized in radioimmunoprecipitation assay buffer (Cell Signaling Technology, MA, US) con-
taining protease inhibitor cocktail (complete EDTA-free ULTRA Tablets, Roche, Germany; phenylmethylsulfonyl 
fluoride, Sigma, MO, US). Protein concentration was measured with bicinchoninic acid assay (Thermo Fischer 
Scientific, MA, US). Equal amounts of protein were mixed with Laemmli buffer, and were separated in 4–15% 
Mini-PROTEAN® TGX™ Gel (Biorad, CA, US). Proteins were transferred onto a polyvinylidene difluoride mem-
brane (Biorad, CA, US). Membrane was blocked with Blotting-Grade Blocker (Biorad, CA, US). Membranes were 
incubated with primary antibodies (anti-Cask, #2878, Cell Signaling Technology, MA, US; anti-calcineurin B type 
1, #AF1348, R&D Systems, MN, US; anti-beta 2 adrenergic receptor,#ab61778, Abcam, UK; anti-GAPDH, #5174, 
Cell Signaling Technology, MA, US), and thereafter with corresponding horseradish-peroxidase-conjugated sec-
ondary antibodies (Cell Signaling Technology, MA, US). After incubating the membranes with Clarity Western 
ECL Substrate (Biorad, CA, US), proteins of interest were detected with ChemiDoc XRS+ System (Biorad, CA, 
US). Band densities were analyzed with planimetry and compared to GAPDH.
Luciferase assay. HeLa cells were co-transfected with luciferase vector (Lightswitch genomics, USA), 
beta-galactosidase vector plasmid and microRNAs (Pre-miR precursors, Thermo Fisher, FI), Lipofectamine 
(Thermo Fisher, FI) served as transfection agent. Luciferase vector was design to contain 3′UTR sequence of rat 
Adrb2 mRNA. For testing, two targeting miRNAs (miR-195 and miR-322) were chosen based of miRNA expres-
sion changes, while miR-106 served as non-targeting control. Each miRNA was used in 100 nM final concen-
tration for transfection. After 24 hour transfection period the cells were harvested and lysed. Beta-galactosidase 
activity with colorimetry and luciferase activity with luminometry was measured in parallel assays. Luciferase 
signal intensity was normalized for beta-galactosidase signal intensity, serving as transfection control. Results are 
expressed in percentage of control.
Gene ontology analysis. Gene ontology analysis was performed using all the predicted miRNA targets 
with the online tool of Gene Ontology Consortium (geneontology.org). Annotations of Rattus norvegicus species 
were adopted from the PANTHER Classification System (pantherdb.org) on 20 June 2016. Biological process 
ontology was applied to calculate enrichment.
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Statistics. qRT-PCR data were analyzed based on the ΔΔCt method. Student’s t-test was performed to analyze 
Western blot results. One-way ANOVA followed by Dunnett’s post hoc test was performed to analyze Luciferase 
results. All tests were two sided, with p < 0.05 as statistically significant level. Data were expressed as mean ± stand-
ard error of mean. Due to multiple hypotheses, Bonferroni correction was applied after gene ontology analysis.
Accession codes. The miRNA microarray datasets were deposited in the ArrayExpress database (https://
www.ebi.ac.uk/arrayexpress/) under the accession number of E-MTAB-3979.
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